Program
teduglutide
Also written as “Teduglutide”, “Teduglutide 0.05 mg/kg/d” and “Teduglutide 0.1 mg/kg/d”.
Its studies are mostly in Short Bowel Syndrome · Crohn Disease · Renal Insufficiency, led by Takeda.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 241 open or running | phase 3since Apr 13, 2004 | Nov 11, 2003 | Feb 10, 2027phase 3 · NCT06973304 |
Also a collaborator on its studies: takeda-development-center-americas-inc, nycomed-germany-gmbh and nps-pharma.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 10 studies since Nov 11, 2003.
- Sep 20, 2010Phase 1 study in Healthy VolunteersNCT01209351 · 36 enrolled · United States
- Mar 13, 2012Phase 3 study in Short Bowel SyndromeNCT01560403 · 14 enrolled · United States
- Sep 23, 2013Phase 3 study in Short Bowel SyndromeNCT01952080 · 42 enrolled · United States, United Kingdom
- Nov 13, 2014Phase 3 study in Short Bowel SyndromeNCT02340819 · 11 enrolled · Japan
- Jan 27, 2016Phase 3 study in Short Bowel SyndromeNCT02682381 · 59 enrolled · United States, Belgium, Canada and more
- Oct 5, 2016Phase 3 study in Short Bowel SyndromeNCT02949362 · 29 enrolled · United States, United Kingdom
- Nov 30, 2016Phase 3 study in Short Bowel SyndromeNCT02980666 · 10 enrolled · Japan
- Aug 10, 2017Phase 3 study in Short Bowel SyndromeNCT03268811 · 9 enrolled · Japan
- May 3, 2018Phase 3 study in Short Bowel SyndromeNCT03571516 · 10 enrolled · Finland, France, Italy and more
- Jun 28, 2018Phase 3 study in Short Bowel SyndromeNCT03596164 · 11 enrolled · Japan
- Aug 28, 2018Phase 3 study in Short Bowel SyndromeNCT03663582 · 7 enrolled · Japan
- Jul 7, 2020Phase 1 study in Healthy VolunteersNCT04465396 · 64 enrolled · United States
- Aug 26, 2021Phase 3 study in Short Bowel SyndromeNCT05027308 · 3 enrolled · Japan
- May 8, 2025Phase 3 study in Short Bowel SyndromeNCT06973304 · 13 enrolled · China
Ahead
- Feb 10, 2027Primary completion: phase 3 study in Short Bowel SyndromeNCT06973304
TargetBeta
“Glucagon-like peptide 2 receptor agonist”ChEMBL 37, by rule
Studies
All 24 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06973304Short Bowel Syndrome · China | 3 | Active, not recruiting | Feb 10, 2027 | 13 |
| NCT05027308Short Bowel Syndrome · Japan | 3 | Completed | Sep 27, 2023 | 3 |
| NCT04465396Healthy Volunteers · United States | 1 | Completed | Aug 20, 2021 | 64 |
| NCT03663582Short Bowel Syndrome · Japan | 3 | Completed | Aug 6, 2019 | 7 |
| NCT03596164Short Bowel Syndrome · Japan | 3 | Completed | Jan 13, 2022 | 11 |
| NCT03571516Short Bowel Syndrome · Finland, France, Italy and more | 3 | Completed | Sep 24, 2020 | 10 |
| NCT03268811Short Bowel Syndrome · Japan | 3 | Completed | Nov 2, 2021 | 9 |
| NCT02980666Short Bowel Syndrome · Japan | 3 | Completed | Jan 21, 2020 | 10 |
| NCT02949362Short Bowel Syndrome · United States, United Kingdom | 3 | Completed | Jul 14, 2020 | 29 |
| NCT02682381Short Bowel Syndrome · United States, Belgium, Canada and more | 3 | Completed | Aug 18, 2017 | 59 |
| NCT02340819Short Bowel Syndrome · Japan | 3 | Completed | Nov 5, 2018 | 11 |
| NCT01952080Short Bowel Syndrome · United States, United Kingdom | 3 | Completed | Jan 9, 2015 | 42 |
| NCT01560403Short Bowel Syndrome · United States | 3 | Completed | Jul 23, 2013 | 14 |
| NCT01209351Healthy Volunteers · United States | 1 | Completed | Nov 8, 2010 | 36 |
| NCT01028924Short Bowel Syndrome · Germany | 1 | Completed | Feb 2010 | 72 |
| NCT01028768Renal Insufficiency · Germany | 1 | Completed | Jan 2010 | 36 |
| NCT00930644Short Bowel Syndrome · United States, Canada, Denmark and more | 3 | Completed | Jan 24, 2013 | 88 |
| NCT00820885Pharmacokinetics and Safety of Elevated Doses · United States | 1 | Completed | Apr 23, 2007 | 95 |
| NCT00819468Hepatic Impairment · United States | 1 | Completed | Aug 23, 2007 | 24 |
| NCT00798967Short Bowel Syndrome · United States, Canada, Denmark and more | 3 | Completed | Jan 25, 2011 | 86 |
| NCT00308438Crohn Disease · United States, Canada | 2 | Completed | Nov 1, 2005 | 67 |
| NCT00172185Short Bowel Syndrome · United States, Belgium, Canada and more | 3 | Completed | Jan 24, 2008 | 65 |
| NCT00081458Short Bowel Syndrome · United States, Belgium, Canada and more | 3 | Completed | Jul 6, 2007 | 84 |
| NCT00072839Crohn Disease · United States, Canada | 2 | Completed | Jul 28, 2005 | 100 |
How it is read
Names in the registry
- “Teduglutide”, 14 entries
- “teduglutide”, 6 entries
- “Teduglutide 0.05 mg/kg/d”, 1 entry
- “Teduglutide 0.1 mg/kg/d”, 1 entry
- “Teduglutide 0.05mg/kg”, 1 entry
Conditions, from the studies’ own filings
- Short Bowel Syndrome, 17 studies
- Crohn Disease, 2 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.